



THE LLS PEDAL TRIAL

Gwen Nichols, MD
Chief Medical Officer



Pediatric Drug Development Paradigm is Broken

How LLS is Disrupting the Status Quo for Children with Cancer

Current State

- Precision medicine progress in adults not seen for children; children are not mini-adults
- Unfavorable business case for pharma industry – cost and operational challenges
- Regulations are not globally uniform
- Data is siloed and not every child has access to sequencing


The LLS Children's Initiative and LLS PedAL

- LLS PedAL will ensure dedicated research testing therapies specially targeting the biological drivers of pediatric cancer
- Master Trials like Beat AML and LLS PedAL allow testing of multiple agents and bring cost-saving efficiencies
- LLS PedAL will create a platform for International cooperation helping pharma companies meet regulatory requirements
- Open source Data Commons created through LLS PedAL will consolidate pediatric acute leukemia data from multiple institutions into a single data set, establish a common language and make that data available to researchers worldwide


OUR SOLUTION

THE LLS CHILDREN'S INITIATIVE

Our vision is for young patients to not only *survive* their cancers, but to *thrive* in their lives after





LLS PedAL Master Trial



BUILDING A SYNTHETIC DATABASE

With an estimate of 100 patients per year in first relapse, the precision of our efficacy assessment will improve significantly

As these patients will be biomarker and clinically annotated, they can serve as patient level data for future efficacy targets for targeted subsets of patients



A MASTER TRIAL WILL IMPROVE THE PRECISION OF OUR EFFICACY ASSESSMENTS